FDA Defends Efficacy Standard In Response To WLF Suit
Executive Summary
There is no constitutional right of access to experimental medicines, FDA declares in a court brief opposing the Abigail Alliance's proposal for a "tiered" drug approval process
You may also be interested in...
Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice
Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice
FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule
FDA will begin the phase out of CFC-containing albuterol products during 2004, according to HHS' semiannual regulatory agenda published in the Dec. 22 Federal Register